KR102653567B1 - 인간 pd1 펩티드 백신 및 이의 용도 - Google Patents
인간 pd1 펩티드 백신 및 이의 용도 Download PDFInfo
- Publication number
- KR102653567B1 KR102653567B1 KR1020197031158A KR20197031158A KR102653567B1 KR 102653567 B1 KR102653567 B1 KR 102653567B1 KR 1020197031158 A KR1020197031158 A KR 1020197031158A KR 20197031158 A KR20197031158 A KR 20197031158A KR 102653567 B1 KR102653567 B1 KR 102653567B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- cancer
- peptide
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477895P | 2017-03-28 | 2017-03-28 | |
| US62/477,895 | 2017-03-28 | ||
| PCT/US2018/024831 WO2018183488A1 (en) | 2017-03-28 | 2018-03-28 | Human pd1 peptide vaccines and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190137826A KR20190137826A (ko) | 2019-12-11 |
| KR102653567B1 true KR102653567B1 (ko) | 2024-04-02 |
Family
ID=63678120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197031158A Active KR102653567B1 (ko) | 2017-03-28 | 2018-03-28 | 인간 pd1 펩티드 백신 및 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11684660B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600398B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7346302B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102653567B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110636855B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018243920B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019020386A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3058393A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2963635T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019131252A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018183488A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021512966A (ja) * | 2018-02-07 | 2021-05-20 | イミュジーン、リミテッドImugene Limited | ワクチン組成物およびその使用 |
| WO2020071869A1 (ko) * | 2018-10-05 | 2020-04-09 | 알엔에이진 주식회사 | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 |
| BR112022005044A2 (pt) | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
| WO2023205796A2 (en) * | 2022-04-21 | 2023-10-26 | Ohio State Innovation Foundation | Human ctla-4 peptide vaccines and uses thereof |
| WO2024211745A1 (en) * | 2023-04-05 | 2024-10-10 | Ohio State Innovation Foundation | Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof |
| CN119019569B (zh) * | 2024-08-19 | 2025-10-24 | 中国人民解放军陆军军医大学 | 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009500298A (ja) * | 2005-06-15 | 2009-01-08 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | Her−2ペプチド |
| WO2016106159A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holding, Inc. | Anti-pd-1 antibodies |
| JP2016526374A (ja) * | 2013-07-12 | 2016-09-05 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | Pd−1抗原またはpd−1リガンド抗原を含むウイルス様粒子 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (cg-RX-API-DMAC7.html) | 1968-10-17 | 1970-08-24 | ||
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| CN1215404A (zh) * | 1996-04-03 | 1999-04-28 | 佩普里瑟奇公司 | 非树状骨架肽载体 |
| FR2765243B1 (fr) | 1997-06-30 | 1999-07-30 | Usinor | Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction |
| CA2534060C (en) * | 2003-07-30 | 2012-06-12 | Vaccine Research Institute Of San Diego | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
| GB0400440D0 (en) * | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| NZ582823A (en) * | 2007-07-27 | 2012-04-27 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| WO2010011315A2 (en) * | 2008-07-25 | 2010-01-28 | Viral Genetics, Inc. | Proteins for use in diagnosing and treating infection and disease |
| US20100234283A1 (en) * | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2623161C2 (ru) * | 2011-04-15 | 2017-06-22 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| EP2744830A4 (en) * | 2012-06-21 | 2015-06-17 | Compugen Ltd | LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| CA2884704C (en) * | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| WO2014161509A1 (en) * | 2013-04-05 | 2014-10-09 | The University Of Hong Kong | Novel pd1 isoforms, and uses thereof for potentiating immune responses |
| DK2992020T3 (da) * | 2013-05-03 | 2020-02-10 | Ohio State Innovation Foundation | Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller |
| TWI720946B (zh) | 2014-08-08 | 2021-03-11 | 美商Vlp醫療股份有限公司 | 包含改質套膜蛋白質e3之類病毒粒子 |
| EP3177640B1 (en) * | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
-
2018
- 2018-03-28 CN CN201880022159.XA patent/CN110636855B/zh active Active
- 2018-03-28 CA CA3058393A patent/CA3058393A1/en active Pending
- 2018-03-28 CN CN202410999144.6A patent/CN118909082A/zh active Pending
- 2018-03-28 US US16/498,929 patent/US11684660B2/en active Active
- 2018-03-28 ES ES18778305T patent/ES2963635T3/es active Active
- 2018-03-28 KR KR1020197031158A patent/KR102653567B1/ko active Active
- 2018-03-28 RU RU2019131252A patent/RU2019131252A/ru unknown
- 2018-03-28 BR BR112019020386-9A patent/BR112019020386A2/pt active Search and Examination
- 2018-03-28 WO PCT/US2018/024831 patent/WO2018183488A1/en not_active Ceased
- 2018-03-28 EP EP18778305.5A patent/EP3600398B1/en active Active
- 2018-03-28 AU AU2018243920A patent/AU2018243920B2/en active Active
- 2018-03-28 JP JP2019553504A patent/JP7346302B2/ja active Active
-
2025
- 2025-03-11 AU AU2025201760A patent/AU2025201760A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009500298A (ja) * | 2005-06-15 | 2009-01-08 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | Her−2ペプチド |
| JP2016526374A (ja) * | 2013-07-12 | 2016-09-05 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | Pd−1抗原またはpd−1リガンド抗原を含むウイルス様粒子 |
| WO2016106159A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holding, Inc. | Anti-pd-1 antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| US11684660B2 (en) | 2023-06-27 |
| RU2019131252A3 (cg-RX-API-DMAC7.html) | 2021-06-01 |
| EP3600398A1 (en) | 2020-02-05 |
| WO2018183488A1 (en) | 2018-10-04 |
| CN110636855A (zh) | 2019-12-31 |
| CN118909082A (zh) | 2024-11-08 |
| CN110636855B (zh) | 2024-08-09 |
| KR20190137826A (ko) | 2019-12-11 |
| ES2963635T3 (es) | 2024-04-01 |
| AU2025201760A1 (en) | 2025-05-22 |
| JP7346302B2 (ja) | 2023-09-19 |
| AU2018243920B2 (en) | 2024-12-12 |
| RU2019131252A (ru) | 2021-04-28 |
| EP3600398B1 (en) | 2023-09-13 |
| US20200197498A1 (en) | 2020-06-25 |
| BR112019020386A2 (pt) | 2020-06-09 |
| EP3600398A4 (en) | 2020-12-30 |
| CA3058393A1 (en) | 2018-10-04 |
| AU2018243920A1 (en) | 2019-10-31 |
| JP2020512375A (ja) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018243920B2 (en) | Human PD1 peptide vaccines and uses thereof | |
| US20230340133A1 (en) | Antibodies Directed Against CD127 | |
| JP7749543B2 (ja) | ヒト抗pd-l1ペプチドワクチン及びその使用方法 | |
| KR102714165B1 (ko) | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 | |
| RS61808B1 (sr) | Antitela i polipeptidi usmereni protiv cd127 | |
| CZ297633B6 (cs) | Pouzití BCMA pro výrobu farmaceutického prípravkupro lécení nádoru exprimujících APRIL | |
| EP3601363B1 (en) | Alt-803 in combination with anti-cd38 antibody for cancer therapies | |
| TR201816597T4 (tr) | Gfr 3'e karşı insan antikorları ve bunların kullanım metotları. | |
| CN115666631A (zh) | Cd40结合蛋白 | |
| HK40119599A (en) | An isolated peptide | |
| US20260007730A1 (en) | Human ctla-4 peptide vaccines and uses thereof | |
| WO2024211745A1 (en) | Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof | |
| HK40013362A (en) | Human pd1 peptide vaccines and uses thereof | |
| HK40067806A (en) | Human anti-pd-l1 peptide vaccines and methods of their use | |
| WO2020033925A9 (en) | Antibodies that bind cd277 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191022 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210325 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230627 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240305 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240328 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240329 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |